Matilda Hagan, MD
Gastroenterology · Baltimore, MDNPI 1346417912
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 74.1% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $17,670, more than ten times the $485 reported in 2019. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $149.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$36K
- AbbVie$4K
- E.r. Squibb & Sons, L.L.C.$4K
- Bristol Myers Squibb$1K
- Janssen Research & Development, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$967
- plus $2K from 24 others
Across 15 payments — averaging $4781.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$36K
- Janssen Research & Development, LLC$35K
What the payments were for
- Consulting fees$27,91357%
- Speaking & faculty fees$6,58413%
- Travel & lodging$5,60711%
- Food & beverage$9,05118%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 93 | $36,459 |
| AbbVie | 75 | $3,712 |
| E.r. Squibb & Sons, L.L.C. | 4 | $3,662 |
| Bristol Myers Squibb | 35 | $1,321 |
| Janssen Research & Development, LLC | 8 | $1,237 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $967 |
| Pfizer | 34 | $750 |
| Medtronic | 2 | $163 |
| QOL Medical, LLC | 5 | $149 |
| Madrigal Pharmaceuticals | 3 | $84 |
| Ferring Pharmaceuticals Inc. | 3 | $78 |
| Aimmune Therapeutics, Inc. | 3 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Braintree Laboratories, Inc. | 4 | $58 |
| Alnylam Pharmaceuticals Inc. | 3 | $47 |
| Lilly USA, LLC | 2 | $40 |
| Digestive Care, Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Sandoz | 1 | $33 |
| Sanofi | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Amgen | 1 | $24 |
| Vivus LLC | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Romark Laboratories, LC | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,176 in reported general payments places this provider in the 90th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 21 | $544,752 |
| Skyrizi On-BodyRisankizumab-Rzaa | 25 | $517,021 |
| RinvoqUpadacitinib | 30 | $242,341 |
| Humira(Cf) PenAdalimumab | 17 | $225,123 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 33 | $5,608 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 35 | $1,962 |
| Colestipol Hcl | 16 | $1,347 |
| Famotidine | 36 | $834 |
| Dicyclomine Hcl | 26 | $622 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 29 | $359 |
| Pantoprazole Sodium | 23 | $344 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 14 | $299 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 17 | $254 |
| Omeprazole | 29 | $242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $36,459 | $544,75221 claims |
| AbbVieRinvoq | $3,712 | $242,34130 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $78 | $5,60833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Baltimore
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Mouen KhashabBaltimore$440K
- Raymond CrossBaltimore$341K
- Paul ThuluvathBaltimore$231K
- Niraj JaniBaltimore$214K
- Aminur KhanBaltimore$118K
- Eric GoldbergBaltimore$110K
- Saowanee NgamruengphongBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.